Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Candel Therapeutics develops off-the-shelf viral immunotherapies targeting solid tumors. Its platforms utilize genetically engineered adenoviruses and herpes simplex viruses to induce tumor cell death and stimulate systemic anti-tumor immune responses. Key products, including CAN-2409 and CAN-3110, aim to treat cancers like prostate, lung, pancreatic, and glioma by converting "cold" tumors into "hot," enhancing immune recognition, with a focus on combination therapies and regulatory approval pathways.
This description was generated via AI from an annual report. Updated about 1 year ago.